TransMedics Group (NASDAQ:TMDX) Director Thomas Gunderson Sells 9,624 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Thomas Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TransMedics Group Stock Down 3.4%

TMDX stock opened at $73.22 on Thursday. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a fifty day simple moving average of $84.57 and a 200 day simple moving average of $113.51. The firm has a market cap of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. During the same period in the previous year, the firm posted $0.70 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the 3rd quarter worth $29,000. Optiver Holding B.V. increased its holdings in shares of TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the period. North Star Investment Management Corp. bought a new position in shares of TransMedics Group during the 1st quarter worth about $30,000. Ascentis Independent Advisors bought a new position in shares of TransMedics Group during the 1st quarter worth about $30,000. Finally, Allworth Financial LP increased its holdings in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on TMDX shares. Stifel Nicolaus cut their target price on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a research report on Tuesday, May 26th. Needham & Company LLC cut their target price on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $134.00.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.